Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 1.00 |
| ▸ | NUAK1 | O60285 | 2/20 | 1.00 |
| ▸ | NUAK2 | Q9H093 | 2/20 | 1.00 |
| ▸ | JAK2 | O60674 | 2/20 | 1.00 |
| ▸ | BLK | P51451 | 2/20 | 1.00 |
| ▸ | BMX | P51813 | 2/20 | 1.00 |
| ▸ | JAK3 | P52333 | 2/20 | 1.00 |
| ▸ | CTSC | P53634 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 1/20 | 1.00 |
| ▸ | BTK | Q06187 | 1/20 | 1.00 |
| ▸ | ITK | Q08881 | 1/20 | 1.00 |
| ▸ | ERBB4 | Q15303 | 1/20 | 1.00 |
| ▸ | DCLK3 | Q9C098 | 1/20 | 1.00 |
| ▸ | EML4 | Q9HC35 | 1/20 | 1.00 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29733655 | 1.00 | EGFR (1.00) | EGFRNUAK1NUAK2JAK2BLK | |
| SCHEMBL29354966 | 1.00 | EGFR (1.00) | EGFRNUAK1NUAK2JAK2BLK | |
| SCHEMBL1706773 | 0.99 | EGFR (0.97) | EGFRNUAK1NUAK2JAK2BLK | |
| SCHEMBL10127856 | 0.94 | EGFR (0.88) | EGFRNUAK1NUAK2JAK2BLK | |
| SCHEMBL9945457 | 0.94 | EGFR (0.91) | EGFRNUAK1NUAK2JAK2BLK | |
| SCHEMBL9945476 | 0.93 | EGFR (0.88) | EGFRNUAK1NUAK2JAK2BLK | |
| SCHEMBL4176137 | 0.93 | EGFR (1.00) | EGFRNUAK1NUAK2JAK2BLK | |
| SCHEMBL10128056 | 0.93 | EGFR (0.87) | EGFRNUAK1NUAK2JAK2BLK | |
| SCHEMBL19705782 | 0.93 | EGFR (0.87) | EGFRNUAK1NUAK2JAK2BLK | |
| SCHEMBL4164770 | 0.93 | EGFR (1.00) | EGFRNUAK1NUAK2JAK2BLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351916-B2 | Method for identification of anti-HIV human miRNA mimics and miRNA inhibitors and anti-HIV pharmaceutical compounds | CSIR (ZA) | 2019-07-16 | — | — | US | claimed |
| WO-2014179528-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | BROWN DENNIS M (US) | 2014-11-06 | — | — | WO | claimed |
| EP-2425830-A1 | Synergistic drug combination for the treatment of cancer | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-03-07 | — | — | EP | claimed |
| US-12194002-B2 | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | BROWN DENNIS (US) | 2025-01-14 | — | — | US | disclosed |
| EP-3604312-B1 | FOURTH-GENERATION EGFR TYROSINE KINASE INHIBITOR | UNIV NAGASAKI (JP) | 2023-11-29 | — | — | EP | disclosed |
| US-11814379-B2 | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-3296905-B1 | METHOD FOR IDENTIFYING NEW MARKERS | ALACRIS THERANOSTICS GMBH (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-20230348434-A1 | NOVEL PYRIMIDINES AS EGFR-INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11673882-B2 | Pyrimidines as EGFR inhibitors and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11584746-B2 | Inhibitors of EGFR and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| EP-4056677-A1 | COMPOSITIONS AND METHODS FOR EPITHELIAL STEM CELL EXPANSION AND CULTURE | The Brigham & Women's Hospital, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| US-20140038981-A1 | NOVEL EGFR MODULATORS AND USES THEREOF | ACEA Therapeutics, Inc. | 2014-02-06 | — | — | US | disclosed |
| US-20140038981-A1 | NOVEL EGFR MODULATORS AND USES THEREOF | ACEA Therapeutics, Inc. | 2014-02-06 | — | — | US | disclosed |
| WO-2013106792-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS. | ACEA BIOSCIENCES INC. (US) | 2013-07-18 | — | — | WO | disclosed |
| CN-103086982-A | Pyrimidine derivative salts | SHANGHAI YIZHI MEDICAL TECH CO | 2013-05-08 | — | — | CN | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2012028334-A2 | MARKER FOR SUNITINIB RESISTANCE FORMATION | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-03-08 | — | — | WO | disclosed |
| EP-2426213-A1 | Marker for sunitnib resistance formation | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-03-07 | — | — | EP | disclosed |
| EP-2425830-A1 | Synergistic drug combination for the treatment of cancer | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094999-A1 | EGFR INHIBITORS AND METHODS OF TREATING DISORDERS | EGFR, ERBB2, ERBB4 | EGFR 1/4885NUAK1 2357/4885NUAK2 1994/4885 |
| US-20230348434-A1 | NOVEL PYRIMIDINES AS EGFR-INHIBITORS AND METHODS OF TREATING DISORDERS | EGFR, ERBB2, ERBB3 | EGFR 1/4885NUAK1 1256/4885NUAK2 1332/4885 |
| US-11814379-B2 | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | ERBB2, EGFR, ERBB3 | EGFR 2/4885NUAK1 976/4885NUAK2 648/4885 |
| US-11584746-B2 | Inhibitors of EGFR and methods of use thereof | EGFR, ERBB2, ERBB3 | EGFR 1/4885NUAK1 1792/4885NUAK2 2038/4885 |
| US-11673882-B2 | Pyrimidines as EGFR inhibitors and methods of treating disorders | EGFR, ERBB2, ERBB3 | EGFR 1/4885NUAK1 1595/4885NUAK2 1610/4885 |
| US-12194002-B2 | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol | HEXD, DDOST, PAICS | EGFR 2685/4885NUAK1 3537/4885NUAK2 4014/4885 |
| US-20140038981-A1 | NOVEL EGFR MODULATORS AND USES THEREOF | EGFR, ERBB2, ERBB3 | EGFR 1/4885NUAK1 2192/4885NUAK2 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.